Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the treatment for adolescents with depression study

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 5, 2009, Pages 519-527

  Kratochvil, Christopher J ^a   May, Diane E ^a   Silva, Susan G ^b   Madaan, Vishal ^a   Puumala, Susan E ^a   Curry, John F ^b   Walkup, John ^c   Kepley, Hayden ^d   Vitiello, Benedetto ^e   March, John S ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO; PSYCHOSTIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; REGRESSION ANALYSIS; SCHOOL CHILD; SCORING SYSTEM; TREATMENT RESPONSE;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 70449104401     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0143     Document Type: Article

References (35)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition. (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
2. Anderson JC, Williams S, McGee R, Silva PA: DSM-III disorders in preadolescent children: Prevalence in a large sample from the general population. Arch Gen Psychiatry 44:69-76, 1987.
3. Angold A, Costello J, Erkanli A: Comorbidity. J Child Psychol Psychiatry 40:57-87, 1999.
4. Antshel KM, Barkley R: Psychosocial interventions in attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 17:421-437, 2008.
5. Atomoxetine ADHD and Comorbid MDD Study Group: Bangs ME, Emslie GE, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, Busner J, Duesenberg DA, Harshawat P, Kaplan SL, Quintana H, Allen AJ, Sumner CR: Efficacy and safety of atomoxetine in adolescents with ADHD and major depression. J Child Adolesc Psychopharmacol 17:407-420, 2007.
6. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M: Treatment of ADHD with fluoxetine: A preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762-767, 1991.
7. Biederman J, Newcorn J, Sprich S: Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:564-577, 1991.
8. Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S: A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry 32:199-204, 1993.
9. Biederman J, Ball S, Monuteaux M, Mick E, Spencer T, McCreary M, Cote M, Farone S: New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry 47:426-434, 2008.
10. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, Perel J, Nelson B: Childhood and adolescent depression: A review of the past 10 years, Part I. J Am Acad Child Adolesc Psychiatry 35:1427-1439, 1996. (Pubitemid 26360928)
11. Conners CK: Technical Manual for the Conners' Rating Scales- Revised. North Tonawanda (New York): Multi-Health Systems, 1997.
12. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L: Bupropion sustained release in adolescents with comorbid attention-deficit= hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40:307-314, 2001.
13. Findling RL: Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series. J Child Adolesc Psychopharmacol 6:165-175, 1996.
14. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT: Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:513-516, 1999.
15. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders. III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12(3 Suppl B):S55-S87, 1998.
16. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
17. Kraemer HC, Wilson GT, Fairburn CG, Agras WS: Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 59:877-883, 2002.
18. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44:915-924, 2005.
19. Lewinsohn PM, Clarke GN: Psychosocial treatments for adolescent depression. ClinPsychol Rev 19:329-342, 1999.
20. MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit=hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073-1086, 1999.
21. Mufson L, Sills R: Interpersonal Psychotherapy for depressed adolescents (IPT-A): An overview. Nord J Psychiatry 60:431-437, 2006.
22. Quintana H, Butterbaugh GJ, Purnell W, Layman AK: Fluoxetine monotherapy in attention-deficit=hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents. Child Psychiatry Hum Dev 37:241-253, 2007.
23. Poznanski EO, Mokros HB: Children's Depression Rating Scale- Revised Manual. Los Angeles (California): Western Psychological Services, 1995.
24. Prince JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner DA, Bostic JQ: A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193-204, 2000. (Pubitemid 30768685)
25. Reinecke MA, Ryan NE, Dubois DL: Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: A review and meta-analysis. J Am Acad Child Adolesc Psychiatry 37:26-34, 1998.
26. Reynolds WM: Professional Manual for the Reynolds Adolescent Depression Scale. Odessa (Florida): Psychological Assessment Resources, 1987a.
27. Reynolds WM: Professional Manual for the Suicidal Ideation Questionnaire. Lutz (Florida): Psychological Assessment Resources, 1987b.
28. SAS Institute, SAS System for Windows, version 8.2. Cary (North Carolina): SAS Institute, 2002.
29. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
30. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO: Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series. J Clin Psychiatry 57:72-76, 1996.
31. The Treatment for Adolescents with Depression Study (TADS) Team: Treatment for Adolescents with Depression Study (TADS): Rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 42:531-542, 2003.
32. The Treatment for Adolescents with Depression Study (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 292:807-820, 2004.
33. The Treatment for Adolescents with Depression Study (TADS) Team: The Treatment for Adolescents with Depression Study (TADS): Demographics and clinical characteristics. J Am Acad Child Adolesc Psychiatry 44:28-40, 2005.
34. The Treatment for Adolescents with Depression Study (TADS) Team: The Treatment for Adolescents with Depression Study (TADS): Long-term effectiveness and safety outcomes. Arch Gen Psychiatry 64:1132-1144, 2007.
35. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T: Nortriptyline in the treatment of ADHD: A chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343-349, 1993.